IDR 246.0
(2.5%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 211.43 Billion IDR | -57.34% |
2022 | 216.83 Billion IDR | -47.9% |
2021 | 416.19 Billion IDR | 120.58% |
2020 | 188.67 Billion IDR | 85.68% |
2019 | 101.61 Billion IDR | 30.76% |
2018 | 77.7 Billion IDR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | 35.99 Billion IDR | -4.22% |
2024 Q2 | 17.51 Billion IDR | -51.33% |
2024 Q3 | 16.37 Billion IDR | -6.53% |
2023 Q3 | 18.83 Billion IDR | 1496.6% |
2023 FY | 92.51 Billion IDR | -57.34% |
2023 Q4 | 37.58 Billion IDR | 99.57% |
2023 Q2 | 1.17 Billion IDR | -96.04% |
2023 Q1 | 29.8 Billion IDR | -41.16% |
2022 Q2 | 60.54 Billion IDR | 5.71% |
2022 Q1 | 57.27 Billion IDR | 48.07% |
2022 FY | 216.83 Billion IDR | -47.9% |
2022 Q4 | 50.66 Billion IDR | 4.8% |
2022 Q3 | 48.34 Billion IDR | -20.15% |
2021 Q2 | 127.44 Billion IDR | 6.1% |
2021 Q4 | 38.68 Billion IDR | -64.48% |
2021 Q3 | 108.89 Billion IDR | -14.56% |
2021 Q1 | 120.12 Billion IDR | 252.49% |
2021 FY | 416.19 Billion IDR | 120.58% |
2020 FY | 188.67 Billion IDR | 85.68% |
2020 Q1 | 24.25 Billion IDR | 0.0% |
2020 Q4 | 34.07 Billion IDR | -62.97% |
2020 Q3 | 92.02 Billion IDR | 279.37% |
2020 Q2 | 24.25 Billion IDR | -0.0% |
2019 FY | 101.61 Billion IDR | 30.76% |
2018 FY | 77.7 Billion IDR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
PT Metro Healthcare Indonesia Tbk | -36.13 Billion IDR | 685.073% |
PT Medikaloka Hermina Tbk | 780.69 Billion IDR | 72.917% |
PT Mitra Keluarga Karyasehat Tbk | 1207.01 Billion IDR | 82.483% |
PT Murni Sadar Tbk | 15.2 Billion IDR | -1290.49% |
PT Famon Awal Bros Sedaya Tbk | 204.41 Billion IDR | -3.434% |
PT Royal Prima Tbk | -4.62 Billion IDR | 4674.557% |
PT Kedoya Adyaraya Tbk | 29.49 Billion IDR | -616.804% |
PT Sarana Meditama Metropolitan Tbk | 47.32 Billion IDR | -346.762% |
PT Siloam International Hospitals Tbk | 1728.28 Billion IDR | 87.766% |
PT Sejahteraraya Anugrahjaya Tbk | 106.26 Billion IDR | -98.98% |